obstructive hypertrophic cardiomyopathy

BMS buys Asian rights to key growth drug Camzyos
Pharmaphorum
Wed, 10/25/23 - 09:46 am
Bristol Myers Squibb
Asia
Camzyos
obstructive hypertrophic cardiomyopathy
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
BioPharma Dive
Thu, 04/28/22 - 10:45 pm
Bristol Myers Squibb
Camzyos
obstructive hypertrophic cardiomyopathy
FDA
BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BioSpace
Mon, 04/4/22 - 10:24 am
Bristol Myers Squibb
FDA
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Fri, 11/19/21 - 11:08 am
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
BioPharma Dive
Mon, 07/19/21 - 11:05 pm
Cytokinetics
clinical trials
CK-274
obstructive hypertrophic cardiomyopathy
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
Mon, 05/11/20 - 11:46 pm
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
Tue, 11/12/19 - 09:49 am
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
MyoKardia cuts all ties to Sanofi
Biopharma Dive
Thu, 07/18/19 - 05:52 pm
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Wed, 01/2/19 - 10:01 am
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy